Merck have suffered a hindrance this week with the withdrawal of their Marketing Authorization Application for ridaforolimus in Europe. The European Medicines Agency (EMA) was evaluating ridaforolimus as a possible maintenance treatment for patients with soft tissue sarcoma or primary malignant bone tumour. Merck have licensed the drug, an M-TOR inhibitor from Ariad Pharmaceuticals.
Merck & Co (also known as MSD) and partner Ariad Pharmaceuticals moved a step closer to EU approval for cancer treatment ridaforolimus yesterday when the European Medicines Agency agreed to start reviewing their marketing application for the drug. Ridaforolimus is an experimental oral mTOR inhibitor developed as a treatment for patients with metastatic soft-tissue or